OBJECTIVE: to determine the association of high sensitivity C-reactive protein (HsCRP) levels with a risk of mobility disability and decline in older adults with and without vascular disease. DESIGN: prospective cohort. SETTING: community-residing population. SUBJECTS: six hundred and twenty-four adults age 70 and older (62% women) with gait and HsCRP assessments. MAIN OUTCOME MEASURES: incident mobility disability (velocity <70 cm/s) and annual rates of decline on gait velocity. RESULTS: elevated HsCRP levels (≥ 3 mg/l) at baseline present in 224 of the 624 eligible subjects was associated with a faster annual decline in gait velocity of 0.91 cm/s (P=0.02). Subjects with elevated HsCRP levels had increased risk of mobility disability (hazard ratio: 1.85, 95% CI: 1.09-3.14). Each one-unit increase in log HsCRP levels in the 406 subjects without prevalent mobility disability was associated with increased risk of mobility disability (hazard ratio: 1.33, 95% CI: 1.05-1.68). The association of baseline HsCRP levels with mobility disability and decline was stronger in the 224 individuals without vascular disease. The associations were not significant in the 400 subjects with vascular disease. CONCLUSIONS: HsCRP levels predict mobility disability and accelerated decline in walking speed in older adults. These associations were stronger in those without vascular disease.
OBJECTIVE: to determine the association of high sensitivity C-reactive protein (HsCRP) levels with a risk of mobility disability and decline in older adults with and without vascular disease. DESIGN: prospective cohort. SETTING: community-residing population. SUBJECTS: six hundred and twenty-four adults age 70 and older (62% women) with gait and HsCRP assessments. MAIN OUTCOME MEASURES: incident mobility disability (velocity <70 cm/s) and annual rates of decline on gait velocity. RESULTS: elevated HsCRP levels (≥ 3 mg/l) at baseline present in 224 of the 624 eligible subjects was associated with a faster annual decline in gait velocity of 0.91 cm/s (P=0.02). Subjects with elevated HsCRP levels had increased risk of mobility disability (hazard ratio: 1.85, 95% CI: 1.09-3.14). Each one-unit increase in log HsCRP levels in the 406 subjects without prevalent mobility disability was associated with increased risk of mobility disability (hazard ratio: 1.33, 95% CI: 1.05-1.68). The association of baseline HsCRP levels with mobility disability and decline was stronger in the 224 individuals without vascular disease. The associations were not significant in the 400 subjects with vascular disease. CONCLUSIONS: HsCRP levels predict mobility disability and accelerated decline in walking speed in older adults. These associations were stronger in those without vascular disease.
Authors: Stephanie Studenski; Subashan Perera; Kushang Patel; Caterina Rosano; Kimberly Faulkner; Marco Inzitari; Jennifer Brach; Julie Chandler; Peggy Cawthon; Elizabeth Barrett Connor; Michael Nevitt; Marjolein Visser; Stephen Kritchevsky; Stefania Badinelli; Tamara Harris; Anne B Newman; Jane Cauley; Luigi Ferrucci; Jack Guralnik Journal: JAMA Date: 2011-01-05 Impact factor: 56.272
Authors: Richard B Lipton; Mindy J Katz; Gail Kuslansky; Martin J Sliwinski; Walter F Stewart; Joe Verghese; Howard A Crystal; Herman Buschke Journal: J Am Geriatr Soc Date: 2003-10 Impact factor: 5.562
Authors: Brenda W J H Penninx; Stephen B Kritchevsky; Anne B Newman; Barbara J Nicklas; Eleanor M Simonsick; Susan Rubin; Michael Nevitt; Marjolein Visser; Tamara Harris; Marco Pahor Journal: J Am Geriatr Soc Date: 2004-07 Impact factor: 5.562
Authors: Matteo Cesari; Brenda W J H Penninx; Marco Pahor; Fulvio Lauretani; Anna Maria Corsi; G Rhys Williams; Jack M Guralnik; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2004-03 Impact factor: 6.053
Authors: Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor Journal: Ageing Res Rev Date: 2015-10-14 Impact factor: 10.895
Authors: Amal A Wanigatunga; Ravi Varadhan; Eleanor M Simonsick; Olga D Carlson; Stephanie Studenski; Luigi Ferrucci; Jennifer A Schrack Journal: J Gerontol A Biol Sci Med Sci Date: 2019-04-23 Impact factor: 6.053
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Joshua Z Willey; Ralph Sacco; Mitchell Sv Elkind Journal: Age Ageing Date: 2017-01-15 Impact factor: 10.668
Authors: Christine K Liu; Asya Lyass; Martin G Larson; Joseph M Massaro; Na Wang; Ralph B D'Agostino; Emelia J Benjamin; Joanne M Murabito Journal: Age (Dordr) Date: 2015-12-23
Authors: Diego Santos-García; T de Deus Fonticoba; E Suárez Castro; A Aneiros Díaz; J M Paz González; M J Feal Panceiras; C García Sancho; S Jesús; P Mir; M Aguilar; P Pastor; J Hernández Vara; O de Fábregues-Boixar; V Puente; A Crespo Cuevas; I González-Aramburu; J Infante; F Carrillo Padilla; M Pueyo; S Escalante; N Bernardo; B Solano; A Cots Foraster; P Martinez-Martin Journal: J Neural Transm (Vienna) Date: 2019-10-31 Impact factor: 3.575
Authors: B Gwen Windham; Steven R Wilkening; Seth T Lirette; Iftikhar J Kullo; Stephen T Turner; Michael E Griswold; Thomas H Mosley Journal: J Am Geriatr Soc Date: 2016-06-16 Impact factor: 5.562
Authors: Daniel P Beavers; Stephen B Kritchevsky; Thomas M Gill; Walter T Ambrosius; Stephen D Anton; Roger A Fielding; Abby C King; W Jack Rejeski; Laura Lovato; Mary M McDermott; Anne B Newman; Marco Pahor; Michael P Walkup; Russell P Tracy; Todd M Manini Journal: J Gerontol A Biol Sci Med Sci Date: 2021-11-15 Impact factor: 6.053